A comparative, randomized, open-label, multicenter study on the efficacy and safety of switch treatment with aripiprazole in schizophrenic out-patients who are experiencing insufficient efficacy with risperidone and/or safety and tolerability issues, while on risperidone

Trial Profile

A comparative, randomized, open-label, multicenter study on the efficacy and safety of switch treatment with aripiprazole in schizophrenic out-patients who are experiencing insufficient efficacy with risperidone and/or safety and tolerability issues, while on risperidone

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2013

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb; Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Feb 2012 Actual end date (April 2007) added as reported by ClinicalTrials.gov.
    • 31 Oct 2007 Status changed from in progress to completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top